henry copeland:

No evidence of added benefit for most new drugs entering German healthcare system: International drug development processes and policies are responsible and must be reformed -- ScienceDaily

And for 125 drugs (58%), the available evidence did not prove an added benefit over standard care in the approved patient population. The situation is particularly shocking in some specialties, they add. For example, in psychiatry/neurology and diabetes, added benefit was shown in just 6% (1/18) and 17% (4/24) of assessments, respectively.
- www.sciencedaily.com